FA 5 Progress Report WV-INBRE - Joan C. Edwards School of ...

More documents

Recommendations

Info

Program Director/Principal Investigator (Last, First, Middle): Rankin, Gary O 584.) Are there potential hazards to laboratory workers (carcinogens, pathogens, ionizing radiation,etc.) involved in the proposed research for next year?A. If yes, identify. N/A N/ANo No5.) Will any of the research-risk categories, not involved next year, be involved in future years?No NoA. If yes, identify. N/A N/APROTECTION AGAINST RESEARCH RISKSY 1. Will human subjects be involved next year?If yes, provide complete the above Targeted/Planned Enrollment Table and the Inclusion EnrollmentReport. Provide the date of IRB approval and enclose with transmittal.09/20/2010Y 2. Will vertebrate animals be used next year?If yes, provide the date of Institutional Animal Care and Use Committee (IACUC) approval and enclosewith transmittal.09/16/2010If no approval date, please explain.Is this IACUC approval date different from the date reported last year?N 3. Will recombinant DNA experiment(s) be conducted next year?N 4. Are there potential hazards to laboratory workers (carcinogens, pathogens, ionizing radiation, etc.)involved in the proposed research for next year? If yes, identify:N5. Will any of the research-risk categories,not involved next year, be involved future years? If yes, identify:PHS 2590 (Rev. 06/09)Continuation Format Page
Program Director/Principal Investigator (Last, First, Middle): Rankin, Gary O 59GENETIC BASIS FOR FAMILIAL COMBINED HYPERLIPIDEMIA (FCHL) (0026)TYPE: Research Subproject%IDeA $: 1.000% IDeA $: 22,500INVESTIGATOR, DEGREEPrimerano, Donald A PHDBaria, Kim RNDementieva, Yulia PHDDenvir, James PHDFan, Jun BS, PHDHenderson, Angela RNNeal, William MDOmar, Hatim FAAP, MDDEPARTMENTBiochemistry &MicrobiologyHealth Research AndEducationMathematicsBiochemistry AndMicrobiologyBiochemistry &MicrobiologyClinical TrialsPediatric CardiologyPediatricsNON-HOST INSTITUTION: STATE,COUNTRYCharleston Area Medical Center, WvUsaEmmanuel College, Ma UsaCharleston Area Medical Center, WvUsaWest Virginia University , Wv UsaUniversity Of Kentucky, Ky UsaTotal # human subjects expected for entire study: 500Total # human subjects enrolled to date: 363SUBPROJECT DESCRIPTIONFamilial Combined Hyperlipidemia (FCHL) is generally defined by elevation of LDL cholesterol andtriglycerides. FCHL affects 0.5-2% of the population of Westernized societies and is one of the mostcommon genetic lipid disorders in patients with coronary artery disease. Recent segregation analyses andlinkage studies suggest an oligogenic mode of inheritance. Our long-range goal is to gain an understandingof the molecular and cellular events that lead to disregulation of cholesterol and triglyceride levels. Theoverall objective of this project is to identify gene(s) that predispose to FCHL using family-based linkageanalysis and association methods. By studying juvenile-based families we hope to identify a form of thedisease with higher heritability. We will also study families that are based on affected adults. The centralhypotheses are that there are specific genes that confer susceptibility to FCHL and that novel gene defectscontribute to juvenile FCHL. The rationale is that once these susceptibility genes have been identified, wewill better understand the molecular pathogenesis in individuals and be able to provide rational, personalizedtreatments or preventative measures can be implemented and tailored to the actual genetic defect. We planto accomplish the objective of this application by pursuing the following two specific aims:1. Identify novel FCHL loci by linkage analysis on a genome-wide set of markers.2. Perform genetic fine mapping on the susceptibility loci in order to narrow the region of interest andidentify variants that encode defective products.The proposed work is innovative because we will analyze Appalachian families based on affected juvenilepatients. These patients have greater genetic risk of developing CVD than adult FCHL patients. It is ourexpectation that this analysis will uncover novel loci and specific genes at those loci that contribute to thedevelopment of FCHL. Our findings will be significant because they will further our understanding of thepathogenesis of vascular disease and because these susceptibility genes represent new targets forpreventative and therapeutic interventions.SUBPROJECT PROGRESSFCH Progress Report Y111. IntroductionFamilial Combined Hyperlipidemia (FCH) is a complex genetic disease in which affected familyPHS 2590 (Rev. 06/09)Continuation Format Page
Page 1 and 2:
Program Director/Principal Investig
Page 3 and 4:
Page 5 and 6:
Page 7 and 8: Program Director/Principal Investig
Page 57: Program Director/Principal Investig
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
show all

FA 5 Progress Report WV-INBRE - Joan C. Edwards School of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?